

ASUNTOS REGULATORIOS
Y FARMACOVIGILANCIA

- 8 SEP 2010

RECIBIDO
ROCHE CHILE LTDA.

to the Regulatory Managers of

Roche Affiliates or

Representative Offices

Basel, August 27, 2010

Ref: T2008-263

DORMICUM® (Midazolam Maleate) Drug Substance

- **T2008-263: Change to a test procedure for the active substance. Minor change to an approved test procedure.**

Dear Ladies and Gentlemen,

We would like to inform you about the following change concerning the DORMICUM drug substance Midazolam maleate.

- **Minor change to an approved test procedure for the active substance. Editorial correction of the analytical procedure for loss on drying.**

In the past a variation for the replacement of the water determination and residual solvents methods by a loss on drying method was submitted and approved. At that time a draft version of the analytical procedure for loss on drying was accidentally used as a reference document. However, the correct and validated test procedure was slightly different to the registered one. This is a pure correction of the text in the document; the correct method has been always used in the analytical laboratory.

Additionally, the opportunity was taken to propose some editorial changes in the description.

A detailed description of the change as well as its justification is provided in a "Rationale for the Change" document. A detailed list of the complete supporting documentation can be found in the provided table of content. This documentation is being sent to you electronically following the e-CTD structure in form of a CD-ROM. A guidance document regarding electronic submission is included along with this cover letter.

We consider the enclosed documentation complete for submission to your authorities. However, you **may reduce** the enclosed documentation according to the requirements of your local authorities. If you have any questions or if you need additional information or documents, please contact me at PTR, Roche Basel (daniel.streich@roche.com)

For our follow-up, may I ask you to complete and return the attached questionnaire by the date indicated? I would also appreciate if you could inform me as soon as the change is approved.

Sincerely,
F. Hoffmann-La Roche Ltd.

Dr. Daniel Streich
PTRD

cc (with enclosures): Dr. L. Spurr-El-Kahef, PDRP

cc (without enclosures): S. Schmeisser, PTCBQ

Attachment

Guidance for Affiliates

TRIC eCTD Style Format

Submitting electronically

Affiliates are encouraged to submit the TRIC dossier electronically when possible (EU Affiliates are encouraged to submit via Eudralink).

Create local cover letter

Upon receipt of the TRIC electronic dossier the affiliate should create their own local cover letter to be addressed to their local Health Authority. The enclosed cover letter addressed to the affiliate can be used as a guide to content.

When submitting electronically according to eCTD standards the local cover letter can be rendered into PDF and used to replace the cover letter placeholder in the Module 1 dossier folder structure retaining the original filename used in the dossier structure (also indicated in the table of contents).

Important Reminder: if the affiliate has replaced, deleted or edited documents in the dossier folder structure and intends on submitting via CD ROM then a new CD will have to be burned to reflect the changed documents.

Submitting the provided CD-ROM

If the affiliate will submit the provided CD ROM to their Health Authority the local cover letter should be provided as a hardcopy.

Submitting Paper Copy

If a paper dossier is required the affiliate can print out the PDF files and compile a paper dossier based on the provided table of contents.

If you have any questions related to the **format** of this dossier please contact:

Andrew Lister, PDRS Basel
andrew.lister@roche.com

If you have any questions related to the **content** of this TRIC change please contact the Technical Regulatory Affairs manager indicated on the cover letter.